Missing Critical Component: Anticoagulation for Stroke Prevention
This 81-year-old woman with atrial fibrillation requires immediate assessment and initiation of anticoagulation therapy for stroke prevention. Her CHA₂DS₂-VASc score is at minimum 3 (age ≥75 years = 2 points, hypertension = 1 point, female sex = 1 point), placing her at high risk for thromboembolic stroke with an annual risk of approximately 5% 1, 2.
Immediate Actions Required
1. Anticoagulation Assessment and Initiation
Oral anticoagulation must be started unless contraindicated 1, 2. With a CHA₂DS₂-VASc score ≥2, Class I evidence supports anticoagulation with either:
- Direct oral anticoagulants (DOACs): Apixaban, rivaroxaban, or dabigatran (preferred over warfarin) 1, 2
- Warfarin: Target INR 2.0-3.0 if DOACs contraindicated 1, 2
Before initiating anticoagulation, you must:
- Assess renal function (creatinine clearance) - required for DOAC dosing and safety 1, 2
- Evaluate bleeding risk factors (falls, prior bleeding, concurrent antiplatelet use)
- Check for contraindications (active bleeding, recent hemorrhagic stroke)
2. Blood Pressure Optimization
Her current BP of 167/78 mmHg remains elevated despite diltiazem. Hypertension control is critically important in atrial fibrillation patients on anticoagulation - it reduces both ischemic stroke risk and the risk of intracerebral hemorrhage, the most devastating complication of anticoagulation 3.
Target BP should be <130/80 mmHg 4. Consider:
- Transitioning from IV diltiazem to oral rate-control agents (diltiazem, metoprolol, or other beta-blockers) 5, 6
- Adding or optimizing antihypertensive therapy (ACE inhibitors or ARBs may provide additional benefit in AF patients) 7, 4
3. Rate Control Optimization
While on diltiazem drip, assess:
- Target heart rate <100 bpm at rest 5
- Consider transition to oral agents once stable (diltiazem extended-release 120-360 mg daily or metoprolol) 5, 6
- Note: Recent evidence suggests diltiazem drips may be associated with longer hospital stays without superior rate control compared to bolus dosing alone 8
Critical Pitfalls to Avoid
Do not discharge this patient without anticoagulation initiated or a clear plan for outpatient initiation. Approximately 50% of eligible AF patients fail to receive appropriate anticoagulation, particularly elderly patients 3. This represents a major gap in care with serious consequences.
Do not use aspirin as monotherapy - it is inadequate for stroke prevention in patients with CHA₂DS₂-VASc ≥2 1, 2.
Do not withhold anticoagulation based on age alone - while elderly patients have higher bleeding risk, the stroke risk without anticoagulation exceeds bleeding risk when BP is controlled 3.
Additional Considerations
Furosemide and Atrial Fibrillation
The temporal relationship between furosemide administration and AF with RVR onset warrants investigation. Furosemide can cause:
- Hypokalemia and hypomagnesemia (check electrolytes, particularly potassium and magnesium) 9
- Volume depletion potentially triggering arrhythmias
- Electrolyte abnormalities should be corrected 9
Monitoring Requirements
- Renal function: Essential before DOAC initiation and at least annually thereafter 1, 2
- Electrolytes: Particularly with ongoing diuretic therapy 9
- Blood pressure: Frequent monitoring during rate control and antihypertensive optimization 10
Transition Planning
- Convert to oral rate-control medication before discharge
- Ensure anticoagulation is therapeutic or bridging plan is clear
- Schedule close follow-up (within 1-2 weeks) to reassess rate control, BP, and anticoagulation safety